Carbapenems are a class of broad-spectrum antibiotics that sit at the top of the treatment hierarchy for serious bacterial infections, often reserved as drugs of last resort when other antibiotics fail. Derived from thienamycin, a natural product discovered in the late 1970s from a soil bacterium, these drugs share the core beta-lactam ring found in penicillins and cephalosporins but carry structural modifications that make them far harder for most bacterial enzymes to destroy. That resilience is exactly what makes carbapenem resistance so alarming when it does emerge.
Where Carbapenems Came From
The carbapenem story begins with a soil organism called Streptomyces cattleya, from which researchers isolated thienamycin in 1976. It was a potent new beta-lactam, but it was also chemically fragile, breaking down readily above pH 8 and reacting with its own amino group.1PubMed. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties That instability made thienamycin impractical as a drug on its own, but of the early carbapenems tested, it showed the greatest antimicrobial activity and became the parent compound from which all subsequent carbapenems were developed.2PubMed Central. Carbapenems: past, present, and future Chemists stabilized the molecule into imipenem, and from there the family grew to include meropenem, ertapenem, and doripenem, each tweaked for different clinical scenarios.
What Makes Carbapenems Structurally Different
All beta-lactam antibiotics share a four-membered ring that is essential for their antibacterial action. In carbapenems, the ring system is modified in a way that gives it two crucial advantages: it still binds the bacterial targets that other beta-lactams hit, and it resists the enzymes that bacteria commonly use to chew up penicillins and cephalosporins. Carbapenems can act as “slow substrates” or even outright inhibitors of many beta-lactamases, meaning the enzymes either break them down very slowly or get stuck trying.2PubMed Central. Carbapenems: past, present, and future This built-in durability is what keeps carbapenems effective in situations where penicillins, cephalosporins, and even extended-spectrum beta-lactams have already been defeated.
How Carbapenems Kill Bacteria
Like all beta-lactams, carbapenems work by targeting penicillin-binding proteins (PBPs), which are enzymes bacteria need to build and maintain their cell walls. When a carbapenem locks onto these proteins, the bacterium can no longer assemble a functional wall, and it eventually swells and bursts. What distinguishes carbapenems from simpler beta-lactams is that they reach a wider set of PBPs across a wider range of bacterial species. That broad reach, combined with their resistance to enzymatic breakdown, is what earned carbapenems their role as the go-to treatment for infections caused by bacteria that produce extended-spectrum beta-lactamases or AmpC enzymes.3PubMed Central. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae
Differences Between Individual Carbapenems
Not all carbapenems cover the same bugs. The family splits roughly into two groups based on spectrum. Imipenem, meropenem, and doripenem are the broader-spectrum agents, with reliable activity against Pseudomonas aeruginosa and many enterococci. Ertapenem is deliberately narrower: it covers most of the same community-acquired pathogens, both aerobic and anaerobic, but it lacks meaningful activity against Pseudomonas and Enterococcus species.4PubMed. Comparative review of the carbapenems That narrower spectrum is not a weakness — it is by design. Ertapenem’s molecular structure was specifically modified to focus on the pathogens most commonly encountered in community-acquired infections while also extending its plasma half-life enough to allow once-daily dosing.5Journal of Antimicrobial Chemotherapy. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties
This distinction matters in practice. Using imipenem or meropenem for an infection that ertapenem could handle is unnecessarily broad and may promote resistance to the agents you want to keep in reserve for Pseudomonas infections. Conversely, reaching for ertapenem when Pseudomonas is suspected would be a mistake, since ertapenem is less active against non-fermenting bacteria.6Journal of Antimicrobial Chemotherapy. Properties and potential of ertapenem
The DHP-I Problem and Why Imipenem Needs a Partner
Imipenem has a pharmacological quirk that its developers had to solve before it could become a useful drug. A kidney enzyme called dehydropeptidase-I (DHP-I) rapidly breaks down imipenem in the renal tubules, which would make the drug useless for urinary tract infections and waste much of the dose before it could do its job.7PubMed. An overview of the pharmacology of imipenem/cilastatin The fix was cilastatin, a specific inhibitor of DHP-I that is co-administered with imipenem in a one-to-one ratio. Cilastatin does not have any antibacterial activity of its own. Its only role is to block the enzyme that would otherwise destroy imipenem in the kidneys, dramatically improving how much active drug reaches the urine.8The American Journal of Medicine. Carbapenems, a new class of beta-lactam antibiotics: Discovery and development of imipenem/cilastatin Meropenem and ertapenem are more stable against DHP-I and do not require a co-administered inhibitor.
How Bacteria Become Resistant to Carbapenems
Carbapenem resistance is one of the most urgent threats in modern infectious disease, and it arises through several distinct routes that often work together in the same bacterium. Understanding these routes matters because the type of resistance mechanism determines which newer drugs might still work.
Carbapenemase Enzymes
The most clinically important mechanism is the production of carbapenemases, enzymes that can directly break apart the carbapenem molecule. These fall into several families. The KPC (Klebsiella pneumoniae carbapenemase) enzymes are the most widespread globally. KPC-2, the best-studied variant, is a serine-based enzyme that has evolved to hydrolyze carbapenems far more efficiently than ordinary beta-lactamases. Researchers have shown that KPC-2 achieves a roughly 20,000-fold increase in its rate of breaking the critical bond in the drug compared to the common TEM-1 beta-lactamase, which handles carbapenems only sluggishly.9PubMed Central. KPC-2 β-lactamase enables carbapenem antibiotic resistance through fast deacylation of the covalent intermediate
Metallo-beta-lactamases (MBLs) are a separate class that use zinc ions rather than a serine residue to chop up beta-lactams. These enzymes can inactivate virtually all beta-lactam antibiotics, carbapenems included.10PubMed Central. Metallo-β-lactamases and a tug-of-war for the available zinc at the host-pathogen interface Well-known MBL families include NDM (New Delhi metallo-beta-lactamase), VIM, and IMP. Because MBLs depend on zinc rather than serine chemistry, they are not inhibited by the conventional beta-lactamase inhibitors used alongside newer carbapenems, which makes MBL-producing infections especially difficult to treat.11PubMed Central. Revisiting the Metallo-β-Lactamase-Mediated Antibiotic Resistance: Exploring Novel Mechanisms and Therapeutic Strategies
A third important family is OXA-48 and its variants. OXA-48 is unusual in that it hydrolyzes penicillins efficiently but breaks down carbapenems more slowly, which can make it harder to detect in routine laboratory testing. The resistance it confers is real but sometimes looks modest on standard susceptibility panels, leading to underdetection.12PubMed Central. Antimicrobial Resistance Conferred by OXA-48 β-Lactamases: Towards a Detailed Mechanistic Understanding
Porin Loss and Efflux Pumps
Not all carbapenem resistance comes from enzymes that destroy the drug. In Pseudomonas aeruginosa, two non-enzymatic mechanisms play a major role. The first involves porin channels, particularly OprD, a protein in the outer membrane that carbapenems use to get inside the cell. When bacteria lose OprD through mutations or reduced expression, imipenem in particular has a much harder time entering, and the bacterium becomes significantly less susceptible.13PubMed Central. Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies Specific mutations in the loops of the OprD protein that form the binding site for imipenem can cause conformational changes that block drug entry even when the porin is still present.14PubMed Central. Investigation of OprD Porin Protein Levels in Carbapenem-Resistant Pseudomonas aeruginosa Isolates
The second mechanism is efflux pumps, molecular machines that actively pump antibiotics back out of the cell. The MexAB-OprM system in Pseudomonas is especially relevant. Overexpression of this pump, often driven by mutations in its regulatory genes, contributes meaningfully to carbapenem resistance.15PubMed. Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa Interestingly, not all carbapenems are equally affected. Meropenem is a substrate of MexAB-OprM, but imipenem is not, meaning that efflux pump overexpression raises meropenem resistance levels without affecting imipenem.16PubMed. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems In clinical isolates from burn wounds, when efflux pumps were chemically blocked, resistance dropped by at least fourfold in most imipenem-resistant and about half of meropenem-resistant strains, confirming the pumps’ role.17PubMed. Role of MexAB-OprM and MexXY-OprM efflux pumps in carbapenem-resistant Pseudomonas aeruginosa from burn wounds
In real-world infections, these mechanisms frequently stack: a single Pseudomonas isolate might combine porin loss with efflux pump overexpression, or a gut bacterium might produce a carbapenemase while also reducing porin expression. The combination pushes resistance levels much higher than any single mechanism alone.
Getting the Most Out of Each Dose
Carbapenems, like other beta-lactams, kill bacteria based on how long the drug concentration stays above the minimum needed to inhibit the pathogen, a concept researchers call “time above MIC.” For carbapenems, bactericidal activity in the body requires the drug to stay above that threshold for at least about 40% of the time between doses.18PubMed Central. Pharmacodynamic optimization of beta-lactams in the patient care setting That is a lower bar than some other beta-lactams need, but in critically ill patients with sepsis, drug levels can fluctuate unpredictably.
This is where extended infusions come in. Instead of giving a dose of meropenem over the standard 30 minutes, clinicians can infuse the same dose over three hours. The total amount of drug is unchanged, but the slower drip keeps blood levels above the target concentration for a larger fraction of the dosing interval. Simulation studies and pharmacokinetic research in septic patients have confirmed that this approach improves the chances of hitting that 40% target, especially against organisms with higher resistance levels.19PubMed Central. Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria Extended infusions do not increase toxicity or cost, making them one of the easiest pharmacologic optimizations available in the ICU.20PubMed. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem
Seizure Risk and Other Side Effects
Carbapenems are generally well tolerated, but they carry a class-associated risk of seizures that clinicians have to keep in mind, particularly with imipenem. The seizure potential of beta-lactams is linked to their ability to bind receptors for GABA, the brain’s main inhibitory neurotransmitter. When those receptors are blocked, neural inhibition drops and the threshold for seizures falls.21PubMed. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations Among the carbapenems, imipenem has the highest reported seizure rates, especially in patients with renal impairment, pre-existing brain lesions, or a history of seizures. Meropenem and ertapenem carry lower risk. Dose adjustments in kidney disease are one of the main ways to reduce this problem.
Other common side effects are typical of beta-lactams broadly: gastrointestinal symptoms (nausea, diarrhea), infusion-site reactions, and occasional rashes. Clostridioides difficile infection is a concern with any broad-spectrum antibiotic course, and carbapenems are no exception. Broad-spectrum use disrupts the normal gut flora, which can open the door for opportunistic pathogens. This collateral damage to the microbiome is one of the key reasons stewardship programs push for narrower antibiotics whenever possible.
When Carbapenems Are the Right Choice and When They Are Not
Carbapenems remain the drugs of choice for serious infections caused by organisms that produce extended-spectrum beta-lactamases or AmpC enzymes. But the reflex to use them for every resistant gram-negative infection has come under scrutiny. A major randomized trial (MERINO) compared piperacillin-tazobactam, a much narrower agent, against meropenem for bloodstream infections caused by ceftriaxone-resistant E. coli or Klebsiella pneumoniae. The trial found that piperacillin-tazobactam did not meet the threshold for noninferiority: 30-day mortality was about 12% in the piperacillin-tazobactam group compared with roughly 4% in the meropenem group.22JAMA. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance That result reinforced meropenem as the safer choice for these bloodstream infections.
A later systematic review and meta-analysis that pooled several observational studies alongside the trial data found a more nuanced picture. Overall mortality did not significantly differ between the two drugs across all infection types. But when the analysis zoomed in on infections where the primary source was not the urinary or biliary tract — infections that tend to be more severe — piperacillin-tazobactam was associated with roughly double the odds of death.23PubMed. Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: A systematic review and meta-analysis The practical takeaway: for urinary-source bloodstream infections, there may be room to consider alternatives to carbapenems in carefully selected patients. For higher-acuity infections from other sources, carbapenems still hold a clear advantage.
Newer Carbapenem Combinations for Resistant Infections
When the bacteria themselves produce carbapenemases, standard carbapenems alone are no longer enough. This drove the development of carbapenem-plus-inhibitor combinations. Meropenem-vaborbactam pairs meropenem with a boronic acid-based inhibitor that specifically neutralizes KPC enzymes. In the TANGO II trial, which enrolled patients with confirmed carbapenem-resistant Enterobacteriaceae infections, clinical cure rates were roughly 66% with meropenem-vaborbactam versus about 33% with the best available alternative therapy at the end of treatment.24Journal of Antimicrobial Chemotherapy. The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections That was a striking improvement over regimens that typically relied on toxic drugs like polymyxins.
Ceftazidime-avibactam (technically a cephalosporin-inhibitor combination, but closely tied to the carbapenem-resistance conversation) and imipenem-cilastatin-relebactam are other options that target KPC-producing infections. All three newer combinations show considerably improved safety and efficacy compared to older polymyxin-based regimens.25PubMed Central. Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target Klebsiella pneumoniae Carbapenemase-Producing Enterobacterales The catch is that none of these inhibitors work well against metallo-beta-lactamases like NDM, because those enzymes use a completely different chemical mechanism. MBL-producing infections remain among the hardest to treat, and finding effective inhibitors for them is one of the most active areas of antibiotic research.
Detecting Carbapenemase Producers in the Lab
Knowing which resistance mechanism you are facing changes treatment decisions, so rapid detection of carbapenemases has become a clinical priority. The Carba NP test, developed for use on isolated bacterial colonies, works by checking whether the organism can break down a carbapenem (imipenem) in a test tube. In validation studies, it was 100% sensitive and specific compared with molecular methods, and it produces a result in under two hours at minimal cost.26PubMed Central. Rapid detection of carbapenemase-producing Enterobacteriaceae
Laboratories now have a growing toolkit beyond the Carba NP test, including immunochromatographic strips that can identify specific carbapenemase types (KPC, NDM, OXA-48, VIM, IMP) from patient specimens. A recent study evaluated one of these rapid strip tests on broth-enriched rectal swabs from ICU patients. After six hours of incubation, the test reached 65% sensitivity and about 98% specificity overall, with higher sensitivity among heavily colonized patients. While not perfect, the approach cut detection time by about 60 hours compared with traditional culture methods.27PubMed Central. Rapid screening for carbapenemase-producing carbapenem-resistant Enterobacterales: clinical implementation of an immunochromatographic test using broth-enriched rectal swabs Other methods in clinical use include mass spectrometry and molecular techniques like whole-genome sequencing, which can identify not just whether a carbapenemase is present but exactly which variant and whether it sits on a mobile genetic element likely to spread.28PubMed. Carbapenemase-producing Enterobacterales infections: recent advances in diagnosis and treatment
Carbapenem Resistance Genes in the Environment
Carbapenem resistance is not just a hospital problem. Resistance genes circulate in the broader environment, and wastewater has emerged as a significant reservoir. A study analyzing wastewater samples found extremely high concentrations of several carbapenemase genes, with KPC, OXA-24/40, and OXA-48 genes detected at especially high levels. VIM and IMP genes were present in roughly 99% of samples, and NDM genes were detectable in about half. The dominant sequence types matched those found in clinical isolates, meaning these were not harmless environmental lookalikes.29PubMed Central. Environmental reservoirs account for high levels of carbapenem resistance genes in wastewater This kind of finding underscores why carbapenem resistance is viewed as a One Health problem spanning hospitals, communities, agriculture, and water systems. Reducing the spread of these genes requires thinking beyond the walls of the ICU.